These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 32466502)
1. Heterogeneity of Metabolic Vulnerability in Imatinib -Resistant Gastrointestinal Stromal Tumor. Huang WK; Gao J; Chen Z; Shi H; Yuan J; Cui HL; Yeh CN; Bränström R; Larsson C; Li S; Lui WO Cells; 2020 May; 9(6):. PubMed ID: 32466502 [TBL] [Abstract][Full Text] [Related]
2. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855 [TBL] [Abstract][Full Text] [Related]
3. Imatinib Regulates Huang WK; Shi H; Akçakaya P; Zeljic K; Gangaev A; Caramuta S; Yeh CN; Bränström R; Larsson C; Lui WO Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638938 [TBL] [Abstract][Full Text] [Related]
4. Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor. Vitiello GA; Medina BD; Zeng S; Bowler TG; Zhang JQ; Loo JK; Param NJ; Liu M; Moral AJ; Zhao JN; Rossi F; Antonescu CR; Balachandran VP; Cross JR; DeMatteo RP Clin Cancer Res; 2018 Feb; 24(4):972-984. PubMed ID: 29246941 [No Abstract] [Full Text] [Related]
5. PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor. Shi Y; Gao X; Hu Q; Li X; Xu J; Lu S; Liu Y; Xu C; Jiang D; Lin J; Xue A; Tan Y; Shen K; Hou Y Lab Invest; 2016 Jun; 96(6):652-60. PubMed ID: 26950487 [TBL] [Abstract][Full Text] [Related]
6. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors. Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002 [TBL] [Abstract][Full Text] [Related]
7. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors. Hsueh YS; Chang HH; Shan YS; Sun HS; Fletcher JA; Li CF; Chen LT Oncogene; 2019 Sep; 38(38):6550-6565. PubMed ID: 31363162 [TBL] [Abstract][Full Text] [Related]
8. SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling. Sugase T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hiramatsu K; Nishida T; Hirota S; Saito Y; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Hanasaki K; Kishimoto T; Mori M; Doki Y; Naka T Gastric Cancer; 2018 Nov; 21(6):968-976. PubMed ID: 29623544 [TBL] [Abstract][Full Text] [Related]
9. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors. Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643 [TBL] [Abstract][Full Text] [Related]
10. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells. Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561 [TBL] [Abstract][Full Text] [Related]
11. Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines. Zhang LY; Huang JS; Pi ZM; Yu MY Int J Clin Exp Pathol; 2015; 8(9):11340-7. PubMed ID: 26617858 [TBL] [Abstract][Full Text] [Related]
12. The role of novel fusion genes in human GIST cell lines derived from imatinib-resistant GIST patients: A therapeutic potential of fusion gene. Cho WC; Shin YK; Na YS; Ryu MH; Ku JL; Kang YK Biochem Biophys Res Commun; 2020 Aug; 529(3):699-706. PubMed ID: 32736695 [TBL] [Abstract][Full Text] [Related]
13. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor. Gao X; Xue A; Fang Y; Shu P; Ling J; Hou Y; Shen K; Qin J; Sun Y; Qin X Oncotarget; 2016 Mar; 7(12):14300-9. PubMed ID: 26893362 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of stromal-interacting molecule 1-mediated store-operated Ca Yang Z; Pan L; Liu S; Li F; Lv W; Shu Y; Dong P Cancer Sci; 2018 Sep; 109(9):2792-2800. PubMed ID: 29957833 [TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells. Sako H; Fukuda K; Saikawa Y; Nakamura R; Takahashi T; Wada N; Kawakubo H; Takeuchi H; Ohmori T; Kitagawa Y PLoS One; 2014; 9(9):e107613. PubMed ID: 25221952 [TBL] [Abstract][Full Text] [Related]
17. Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors. Lu X; Pang Y; Cao H; Liu X; Tu L; Shen Y; Jia X; Lee JC; Wang Y Cancer Res; 2021 May; 81(9):2481-2494. PubMed ID: 33727226 [TBL] [Abstract][Full Text] [Related]
18. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo. Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors. Boichuk S; Dunaev P; Galembikova A; Mustafin I; Valeeva E Anticancer Drugs; 2018 Jul; 29(6):549-559. PubMed ID: 29697413 [TBL] [Abstract][Full Text] [Related]
20. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate. Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]